4-Methyl-α-methyltryptamine
| Clinical data | |
|---|---|
| Other names | 4-Me-αMT; 4-Me-AMT; 4-Methyl-αMT; 4-Methyl-AMT; 4,α-Dimethyltryptamine; 4,α-DMT; MP-809; MP809; Methyl-2-methyltryptamine |
| Routes of administration | Oral |
| Drug class | Antidepressant |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H16N2 |
| Molar mass | 188.274 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
4-Methyl-α-methyltryptamine (4-Me-αMT or 4-Me-AMT), also known as 4,α-dimethyltryptamine (4,α-DMT) and by its developmental code name MP-809, is an experimental antidepressant of the tryptamine and α-alkyltryptamine families. It is closely structurally related to serotonergic psychedelics and entactogens like α-methyltryptamine (αMT) and α-ethyltryptamine (αET). 4-Me-αMT was investigated as an antidepressant by Sandoz in Canada in the early 1960s, although it was never marketed.